Immunogenicity and safety of seasonal influenza vaccination in patients with classic Kaposi's sarcoma

Monica Cappelletti, Adriano Taddeo, Elena Colombo, Lucia Brambilla, Monica Bellinvia, Fabrizio Pregliasco, Maria L. Villa, Silvia Della Bella

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Classic Kaposi's sarcoma (cKS) is a human herpesvirus-8 (HHV-8)-associated lympho-angioproliferative tumor typically occurring in the elderly. It is associated with HHV-8-driven perturbed balance of peripheral B-cell subsets, which may have an impact on immune responses to antigenic stimulation. We took advantage of the common practice of cKS patients to undergo seasonal influenza vaccination because of advanced age and analyzed the immunogenicity and safety of licensed trivalent influenza vaccine in 46 cKS patients and 44 matched controls. Licensure criteria for immunogenicity were fulfilled in both groups. Four weeks after vaccination, hemagglutination-inhibition antibody titers against each viral strain contained in the vaccine increased in patients and controls (all P0.001). Protection against at least one strain was achieved by 96% of cKS and 91% of control subjects. Protection against all strains persisted after 12 weeks, demonstrating a long-lasting response to vaccination. The vaccine was equally well tolerated by patients and controls, as assessed by evaluating solicited local and systemic reactions to the vaccine, and appearance or increase of antinuclear autoantibodies. HHV-8 virological rebound was observed in four cKS patients, but was not accompanied by progression of KS lesions. We conclude that seasonal influenza vaccine given to cKS patients is immunogenic and safe.

Original languageEnglish
Pages (from-to)2414-2421
Number of pages8
JournalJournal of Investigative Dermatology
Volume132
Issue number10
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Kaposi's Sarcoma
Human Influenza
Vaccination
Safety
Human Herpesvirus 8
Vaccines
Influenza Vaccines
Autoantibodies
B-Lymphocyte Subsets
Tumors
Cells
Hemagglutination
Licensure
Antibodies
Neoplasms

ASJC Scopus subject areas

  • Dermatology
  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Immunogenicity and safety of seasonal influenza vaccination in patients with classic Kaposi's sarcoma. / Cappelletti, Monica; Taddeo, Adriano; Colombo, Elena; Brambilla, Lucia; Bellinvia, Monica; Pregliasco, Fabrizio; Villa, Maria L.; Della Bella, Silvia.

In: Journal of Investigative Dermatology, Vol. 132, No. 10, 10.2012, p. 2414-2421.

Research output: Contribution to journalArticle

Cappelletti, M, Taddeo, A, Colombo, E, Brambilla, L, Bellinvia, M, Pregliasco, F, Villa, ML & Della Bella, S 2012, 'Immunogenicity and safety of seasonal influenza vaccination in patients with classic Kaposi's sarcoma', Journal of Investigative Dermatology, vol. 132, no. 10, pp. 2414-2421. https://doi.org/10.1038/jid.2012.151
Cappelletti, Monica ; Taddeo, Adriano ; Colombo, Elena ; Brambilla, Lucia ; Bellinvia, Monica ; Pregliasco, Fabrizio ; Villa, Maria L. ; Della Bella, Silvia. / Immunogenicity and safety of seasonal influenza vaccination in patients with classic Kaposi's sarcoma. In: Journal of Investigative Dermatology. 2012 ; Vol. 132, No. 10. pp. 2414-2421.
@article{32f0497f0a504db3a3fb306ef018d1c2,
title = "Immunogenicity and safety of seasonal influenza vaccination in patients with classic Kaposi's sarcoma",
abstract = "Classic Kaposi's sarcoma (cKS) is a human herpesvirus-8 (HHV-8)-associated lympho-angioproliferative tumor typically occurring in the elderly. It is associated with HHV-8-driven perturbed balance of peripheral B-cell subsets, which may have an impact on immune responses to antigenic stimulation. We took advantage of the common practice of cKS patients to undergo seasonal influenza vaccination because of advanced age and analyzed the immunogenicity and safety of licensed trivalent influenza vaccine in 46 cKS patients and 44 matched controls. Licensure criteria for immunogenicity were fulfilled in both groups. Four weeks after vaccination, hemagglutination-inhibition antibody titers against each viral strain contained in the vaccine increased in patients and controls (all P0.001). Protection against at least one strain was achieved by 96{\%} of cKS and 91{\%} of control subjects. Protection against all strains persisted after 12 weeks, demonstrating a long-lasting response to vaccination. The vaccine was equally well tolerated by patients and controls, as assessed by evaluating solicited local and systemic reactions to the vaccine, and appearance or increase of antinuclear autoantibodies. HHV-8 virological rebound was observed in four cKS patients, but was not accompanied by progression of KS lesions. We conclude that seasonal influenza vaccine given to cKS patients is immunogenic and safe.",
author = "Monica Cappelletti and Adriano Taddeo and Elena Colombo and Lucia Brambilla and Monica Bellinvia and Fabrizio Pregliasco and Villa, {Maria L.} and {Della Bella}, Silvia",
year = "2012",
month = "10",
doi = "10.1038/jid.2012.151",
language = "English",
volume = "132",
pages = "2414--2421",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Immunogenicity and safety of seasonal influenza vaccination in patients with classic Kaposi's sarcoma

AU - Cappelletti, Monica

AU - Taddeo, Adriano

AU - Colombo, Elena

AU - Brambilla, Lucia

AU - Bellinvia, Monica

AU - Pregliasco, Fabrizio

AU - Villa, Maria L.

AU - Della Bella, Silvia

PY - 2012/10

Y1 - 2012/10

N2 - Classic Kaposi's sarcoma (cKS) is a human herpesvirus-8 (HHV-8)-associated lympho-angioproliferative tumor typically occurring in the elderly. It is associated with HHV-8-driven perturbed balance of peripheral B-cell subsets, which may have an impact on immune responses to antigenic stimulation. We took advantage of the common practice of cKS patients to undergo seasonal influenza vaccination because of advanced age and analyzed the immunogenicity and safety of licensed trivalent influenza vaccine in 46 cKS patients and 44 matched controls. Licensure criteria for immunogenicity were fulfilled in both groups. Four weeks after vaccination, hemagglutination-inhibition antibody titers against each viral strain contained in the vaccine increased in patients and controls (all P0.001). Protection against at least one strain was achieved by 96% of cKS and 91% of control subjects. Protection against all strains persisted after 12 weeks, demonstrating a long-lasting response to vaccination. The vaccine was equally well tolerated by patients and controls, as assessed by evaluating solicited local and systemic reactions to the vaccine, and appearance or increase of antinuclear autoantibodies. HHV-8 virological rebound was observed in four cKS patients, but was not accompanied by progression of KS lesions. We conclude that seasonal influenza vaccine given to cKS patients is immunogenic and safe.

AB - Classic Kaposi's sarcoma (cKS) is a human herpesvirus-8 (HHV-8)-associated lympho-angioproliferative tumor typically occurring in the elderly. It is associated with HHV-8-driven perturbed balance of peripheral B-cell subsets, which may have an impact on immune responses to antigenic stimulation. We took advantage of the common practice of cKS patients to undergo seasonal influenza vaccination because of advanced age and analyzed the immunogenicity and safety of licensed trivalent influenza vaccine in 46 cKS patients and 44 matched controls. Licensure criteria for immunogenicity were fulfilled in both groups. Four weeks after vaccination, hemagglutination-inhibition antibody titers against each viral strain contained in the vaccine increased in patients and controls (all P0.001). Protection against at least one strain was achieved by 96% of cKS and 91% of control subjects. Protection against all strains persisted after 12 weeks, demonstrating a long-lasting response to vaccination. The vaccine was equally well tolerated by patients and controls, as assessed by evaluating solicited local and systemic reactions to the vaccine, and appearance or increase of antinuclear autoantibodies. HHV-8 virological rebound was observed in four cKS patients, but was not accompanied by progression of KS lesions. We conclude that seasonal influenza vaccine given to cKS patients is immunogenic and safe.

UR - http://www.scopus.com/inward/record.url?scp=84866418833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866418833&partnerID=8YFLogxK

U2 - 10.1038/jid.2012.151

DO - 10.1038/jid.2012.151

M3 - Article

VL - 132

SP - 2414

EP - 2421

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 10

ER -